Study on homocysteine levels and methylenetetrahydrofolate reductase gene variant (C677T) in a population of Buenos Aires city

Clinical and Experimental Hypertension

Volumn 30, Issue 7, 2008, Pages 574-584

  Fridman, Osvaldo ^a,c   Porcile, Rafael ^b   Vanasco, Virginia ^a   Junco, Mariano N ^a   Gariglio, Luis ^b   Potenzoni, Miguel A ^b   Bañes, Isabel ^b   Morales, Analía ^a  

^a UNIVERSIDAD ABIERTA INTERAMERICANA   (Argentina)

^b Hospital Universitario   (Argentina)

^c Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Body mass index; Genetic polymorphism; Homocysteine; Methylenetetrahydrofolate reductase (MTHFR); MTHFR C677T

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTIHYPERTENSIVE AGENT; CYTOSINE; HOMOCYSTEINE; THYMINE;

ADULT; AGED; ALLELE; AMINO ACID BLOOD LEVEL; ANAMNESIS; ANTIHYPERTENSIVE THERAPY; ARGENTINA; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CROSS-SECTIONAL STUDY; FEMALE; GENE; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEALTH CENTER; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LONG TERM CARE; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; OBESITY; POPULATION RESEARCH; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ALLELES; ARGENTINA; BASE SEQUENCE; CROSS-SECTIONAL STUDIES; DNA PRIMERS; FEMALE; GENE FREQUENCY; GENOTYPE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; VASCULAR DISEASES; YOUNG ADULT;

EID: 54049156454     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960802251958     Document Type: Article

References (48)

1. Selhub J. Homocystine metabolism. Annu Rev Nutr. 1999;19:217-246.
2. Dudman NP, Guo XW, Gordon RB, Dawson PA, Wilcken DE. Human homocysteine catabolism: Three major pathways and their relevance to development of arterial occlusive disease. J Nutr. 1996;126(4 Suppl.):1295S-300S.
3. Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oost BA, et al. Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet. 1996;58:35-41.
4. Albert CM, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. 2002;105:2595-2599.
5. Sundström J, Sullivan L, D'Agostino RB, Jacques PF, Selhub J, Rosenberg IH, et al. Plasma homocysteine, hypertension incidence, and blood pressure tracking: The Framingham Heart Study. Hypertension. 2003;42:1100-1105.
6. Adachi H, Hirai Y, Fujiura Y, Matsuoka H, Satoh A, Imaizumi T. Plasma homocysteine levels and atherosclerosis in Japan: Epidemiological study by use of carotid ultrasonography. Stroke. 2002;33:2177-2181.
7. Sainani GS, Sainani R. Homocysteine and its role in the pathogenesis of atherosclerotic vascular disease. J Assoc Physicians India. 2002;50 (Suppl.):5-8.
8. Boers GH. Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease. Semin Thromb Hemost. 2000;26:291-295.
9. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr. 1992;12:279-298.
10. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004;350:2033-2041.
11. Aksov N, Aksov M, Cakmak M, Gergerlioglu HS, Davotoglu V, Sovdinc S, et al. Increased homocysteine in heart failure: A result of renal impairment? Clin Chem Lab Med. 2006;44:1324-1329.
12. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol. 1998;55:1449-1455.
13. Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: A thermolabile variant of methylentetrahydrofolate reductase. Am J Hum Genet. 1988;43:414-421.
14. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
15. Rosenberg N, Murata M, Ikeda Y, Opare-Sem O, Zivelin A, Geffen E, et al. The frequent 5,10-methylenetetrahydrofolate reductase C677T polymorphism is associated with a common haplotype in whites, Japanese, and Africans. Am J Hum Genet. 2002;70:758-762.
16. Esfahani ST, Cogger EA, Caudill MA. Heterogeneity in the prevalence of methylenetetrahydrofolate reductase gene polymorphisms in women of different ethnic groups. Am Diet Assoc. 2003;103:200-207.
17. Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Goyette P, Rosenblatt DS, et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol. 1997;17:569-573.
18. Brugada R, Marian AJ. A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. Atherosclerosis. 1997;128:107-112.
19. Thogersen AM, Nilsson TK, Dahlen G, Jansson JH, Boman K, Huhtasaari F, et al. Homozygosity for the C677 → T mutation of 5,10- methylenetetrahydrofolate reductase and total plasma homocyst(e)ine are not associated with greater than normal risk of a first myocardial infarction in northern Sweden. Coron Artery Dis. 2001;12:85-90.
20. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ. 2002;325:1202-1206.
21. Lewis SJ, Ebrahim S, Smith GD. Meta-analysis of MTHFR 677C-T polymorphism and coronary heart disease: Does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ. 2005;331:1053-1058.
22. Ubbink JB, van der Merwe A, Vermaak WJ, Delport R. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Investig. 1993;71:993-998.
23. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999;340:1449-1454.
24. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
25. Heux S, Morin F, Lea RA, Ovcaric M, Tajouri L, Griffiths LR. The methylentetrahydrofolate reductase gene variant (C677T) as a risk factor for essential hypertension in Caucasians. Hypertens Res. 2004;27:663-667.
26. Castañon MM, Lauricella AM, Kordich L, Quintana I. Plasma homocysteine cutoff values for venous thrombosis. Clin Chem Lab Med. 2007;45:232-236.
27. Beneš P, Jurajda M, Žaloudík J, Izakovicová- Hollá L, Vácha J. C766T low-density lipoprotein receptor-related protein 1 (LRP1) gene polymorphism and susceptibility to breast cancer. Breast Cancer Res. 2003;5:R77-R81.
28. Selhub J, Jacques PF, Wilson PW, Rush P, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993;270:2693-2698.
29. Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Secic M, et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: Sex difference and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem. 1994;40:873-881.
30. Van der Mooren MJ, Wouters MG, Blom HJ, Schellekens LA, Eskes TK, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest. 1994;24:733-736.
31. Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol. 1999;10:891-900.
32. Lim U, Cassano PA. Homocysteine and blood pressure in the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2002;156:1105-1113.
33. Pierdomenico SD, Bucci A, Lapenna D, Lattanzio FM, Talone L, Cuccurullo F, et al. Circulating homocysteine levels in sustained and white coat hypertension. J Hum Hypertens. 2003;17:165-170.
34. Curgunlu A, Karter Y, Uzun H, Aydin S, Erturk N, Vehid S, et al. Hyperhomocysteinemia: An additional risk factor in white coat hypertension. Int Heart J. 2005;46:245-254.
35. Rodrigo R, Passalacqua W, Araya J, Orellana M, Rivera G. Homocysteine and essential hypertension. J Clin Pharmacol. 2003;43:1299-1306.
36. Lip GY, Edmunds E, Martin SC, Jones AF, Blann AD, Beevers DG. A pilot study of homocyst(e)ine levels in essential hypertension: relationship to von Willebrand factor, an index of endothelial damage. Am J Hypertens. 2001;14:627-631.
37. van Dijk RA, Rauwerda JA, Steyn M, Twisk JW, Stehouwer CD. Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery, endothelium-dependent vasodilation, or carotid artery stiffness: A two-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol. 2001;21:2072-2079.
38. Outinen PA, Sood SK, Liaw PC, Sarge KD, Maeda N, Hirsh J, et al. Characterization of the stress inducing effects of homocysteine. Biochemistry. 1998;332:213-221.
39. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, et al. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA. 1994;91:6369-6373.
40. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997;17:2074-2081.
41. Schini-Kerth VB. Homocysteine, a proinflammatory and proatherosclerotic factor: Role of intracellular reactive oxygen species. Circ Res. 2003;93:271-273.
42. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest. 1996;98:5-7.
43. Stehouwer CD, van Guldener C. Does homocysteine cause hypertension? Clin Chem Lab Med. 2003;41:1408-1411.
44. Koubaa N, Nakbi A, Smaoui M, Abid N, Chaaba R, Abid M, et al. Hyperhomocysteinemia and elevated ox-LDL in Tunisian type 2 diabetic patients: Role of genetic and dietary factors. Clin Bioochem. 2007;40:1007-1014.
45. Fletcher O. Kessling AM. MTHFR association with arteriosclerotic vascular disease? Hum Genet. 1998;103:11-21.
46. Qian X, Lu Z, Tan M, Liu H, Lu D. A meta-analysis of association between C677T polymorphism in the methylenetetrahydrofolate reductase gene and hypertension. European Journal of Human Genetics. 2007;15:1239-1245.
47. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr. 2001;73:613-621.
48. Girelli D, Friso S, Trabetti E, Olivieri O, Russo C, Pessotto R, et al. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: Evidence for an important genetic-environmental interaction. Blood. 1998;91:4158-4163.